Telmisartan vs Olmesartan in CHF Patients with Metabolic Syndrome

12 Dec, 10

0

Telmisartan superior to Olmesartan in CHF patients with metabolic syndrome

Aim

To compare the effects of telmisartan and olmesartan in patients with chronic heart failure (CHF) and metabolic syndrome.

Patients with CHF and metabolic syndrome receiving 40 mg/day telmisartan (n = 20)

Phase I: All patients received 20 mg/day olmesartan for 3 months in place of telmisartan

Phase II: All patients were switched back to telmisartan 40 mg/day for 3 months

6 months

Early morning systolic and diastolic blood pressure was significantly increased with olmesartan which returned to baseline values with telmisartan
Olmesartan significantly increased the plasma BNP levels which were brought back to the baseline with telmisartan
Changes in plasma BNP levels correlated with early morning changes in systolic blood pressure with both telmisartan and olmesartan
Increase in lipids (serum total cholesterol, LDL cholesterol and triglyceride levels) were observed with olmesartan and returned to baseline with telmisartan

Telmisartan is superior to olmesartan in managing early morning blood pressure and lipid metabolism in patients with CHF and metabolic syndrome.

Journal of Cardiac Failure, 2007;13(6) Suppl 1:S47

0